U.S. Stock News

American International Group (AIG) opened 2026 with Q1 results that put the focus squarely on the income statement, as revenue came in at US$6.7b and basic EPS landed at US$1.42 on net income of US$763m. The company has seen revenue move from US$6.5b in Q1 2025 to US$6.7b in Q1 2026, while basic EPS over that stretch ranged from US$1.18 in Q1 2025 to US$1.42 in the latest quarter. This sets the stage for investors to weigh these headline figures against a backdrop of improving trailing net...

OneSpan (OSPN) Q1 2026 earnings snapshot OneSpan (OSPN) has opened 2026 with Q1 revenue of US$65.9 million and basic EPS of US$0.31, setting the tone for investors assessing how the business is converting its software demand into bottom line results. Over the past year, the company has seen trailing twelve month revenue sit at US$245.8 million with basic EPS of US$1.84, alongside earnings growth of 20.4% and net margins at 28.5% compared to 24% a year earlier. This provides useful context for...

LPL Financial Holdings (LPLA) opened 2026 with Q1 revenue of about US$4.8b and basic EPS of US$4.45, as investors weigh these headline figures against a reported net margin of 5% over the trailing 12 months that was affected by a US$732.0m one off loss. The company has seen quarterly revenue move from US$3.4b in Q4 2024 to US$3.6b in Q1 2025 and then to about US$4.8b in Q1 2026. Over the last six reported periods, trailing 12 month basic EPS has ranged from US$14.17 to US$11.25, placing...

Jade Biosciences (NasdaqCM: JBIO) appointed Edward R. Conner, M.D. as Chief Medical Officer. The company elevated Andrew King, M.D., Ph.D. to President, Research & Development. These leadership changes focus on clinical development, regulatory strategy, and R&D continuity for Jade's autoimmune pipeline. Jade Biosciences, listed on NasdaqCM under the ticker JBIO, is focused on developing therapies for autoimmune conditions, an area that continues to attract capital and partnerships across...

PBF Energy (PBF) opened 2026 with Q1 revenue of US$7.9b and basic EPS of US$1.69, alongside net income excluding extra items of US$198.3m, setting a clear marker after a volatile run of recent quarters. The company has seen quarterly revenue move from US$7.1b in Q1 2025 to US$7.9b in Q1 2026, while EPS shifted from a loss of US$3.53 in Q1 2025 to a profit of US$1.69 in the latest period. This points to a very different margin profile as investors gauge how durable this reset may be. See our...

Investors may be wondering whether Aurora Innovation's share price reflects its true worth, or if the market is mispricing the story right now. The stock recently closed at US$6.13, with returns of 24.8% over 7 days, 46.7% over 30 days, 58.4% year to date, and a 24.7% decline over the past year, alongside a very large gain over 3 years. Recent coverage has focused on how autonomous driving and AI related names are being reassessed by investors, as attention shifts to companies tied to real...

If you are wondering whether Corcept Therapeutics at around US$51.42 is attractively priced or already stretched, starting with a clear view of valuation can help frame your next move. The stock has seen sharp swings recently, with returns of 11.6% over 7 days, 22.5% over 30 days, 34.6% year to date, but a 29.3% decline over the past year and gains of 113.6% over 3 years and 143.7% over 5 years. Recent coverage has focused on how this price history shapes expectations for Corcept...

For investors considering whether Travelers Companies at around US$304.72 represents fair value or whether the price may be ahead of itself, this article examines what the available numbers indicate about the stock. The share price has moved by 0.7% over the past week, 4.9% over the last month, 6.8% year to date and 15.8% over the past year. These figures provide useful context before assessing the underlying value. Recent news coverage has focused on Travelers Companies as a major U.S...

Why CarGurus Stock Is on Investors’ Radar CarGurus (CARG) has drawn investor interest after recent trading left the shares around US$37.04, with returns over the past month and past 3 months outpacing its year to date performance. See our latest analysis for CarGurus. That recent move to US$37.04 follows a 10.4% 30 day share price return and a 14.3% 90 day share price return, set against a year to date share price return that is slightly negative and a 31.4% 1 year total shareholder return...

Omega Healthcare Investors (OHI) opened 2026 with Q1 revenue of US$323 million and basic EPS of US$0.47, alongside funds from operations of US$249 million and FFO per share of US$0.84, setting a clear snapshot of cash generation and earnings at the start of the year. Over the past reported quarters, revenue has moved from US$277 million in Q1 2025 to US$319 million in Q4 2025 and EPS has ranged between US$0.34 and US$0.60 over that period. This gives investors a recent history of how the top...

Wondering if American Healthcare REIT is reasonably priced at around US$50 a share, or if the market is getting ahead of itself? This article walks through what the current numbers actually say about value. The stock recently closed at US$50.15, with returns of 0.1% over 7 days, 5.5% over 30 days, 6.2% year to date and 57.7% over the past year. This naturally raises questions about how much of the story is already reflected in the price. Recent coverage has focused on American Healthcare...

Align Technology (ALGN) opened 2026 with Q1 revenue of about US$1.0 billion and basic EPS of US$1.58, setting the tone for how investors will read the rest of the year. The company has seen quarterly revenue move from US$979.3 million in Q1 2025 through US$995.2 million in Q4 2024 to just over US$1.0 billion in the latest quarter, while basic EPS over the same span ranged from US$1.27 in Q1 2025 to US$1.89 in Q4 2025 before landing at US$1.58 in Q1 2026. This provides a clear run-rate on both...

O'Reilly Automotive (ORLY) opened 2026 with Q1 revenue of US$4.6b and basic EPS of US$0.72, supported by trailing twelve month revenue of US$18.2b and EPS of US$3.08 that point to earnings growth of 9.5% over the past year. Over the last five reported quarters, the company has seen revenue move from US$4.1b in Q1 2025 to US$4.6b in Q1 2026, while quarterly EPS ranged between US$0.63 and US$0.86 across that period as trailing net income reached US$2.6b. With net profit margins running at...

This article examines whether StoneCo, trading at around US$10.98, could be considered a bargain or a value trap by focusing on what the current share price might imply about the company. The stock has experienced significant recent volatility, with a 24.5% decline over the last week, a 22.2% decline over the last month, and a 25.3% decline year to date. Over longer periods, the 1 year return shows a 4.3% decline and the 5 year return a 78.3% decline. Recent commentary around StoneCo has...

Structure Therapeutics (NasdaqGM:GPCR) plans multiple presentations at the 86th American Diabetes Association Scientific Sessions. The company will share new safety, efficacy, and dosing data for its oral GLP-1 receptor agonist aleniglipron. Additional data will cover a novel amylin receptor agonist combination, including findings on weight loss effects. The presentations focus on combination approaches in obesity and diabetes treatment development. Structure Therapeutics focuses on oral...

If you are wondering whether Camtek's current share price reflects its underlying value, you are not alone. That question is exactly what this article will help you think through. Camtek's stock has been volatile recently, with a 2% decline over the last week, a 26.6% gain over the last 30 days, a 66.2% return year to date, and a 191.3% return over the last year, along with very large multi year gains. These moves have put Camtek firmly on many investors' radars, and recent coverage has...

Clorox, NYSE:CLX, has completed its acquisition of GOJO Industries, the owner of the Purell brand. The deal adds a broad health and hygiene portfolio to Clorox's existing cleaning and household products. This transaction reflects a move to broaden Clorox's exposure beyond traditional household categories. Clorox enters this deal with its shares at $96.44, after a 27.3% decline over the past year and a 38.1% decline over the past five years. The acquisition of GOJO and Purell gives the...

L3Harris Technologies (LHX) has kicked off its Q1 2026 reporting cycle with investors looking back at a steady run of quarterly numbers, where 2025 revenue ranged from US$5,132 million to US$5,659 million and basic EPS moved between US$1.60 and US$2.47. Over the last year, the company has seen total revenue hold around US$21.2 billion on a trailing basis, while trailing EPS has tracked between US$7.91 and US$9.35. This provides a clear sense of consistent top line scale and earnings power as...

If you are wondering whether Warner Bros. Discovery at around US$27.05 is still offering value after a strong run, this breakdown will help you understand what the current price actually reflects. The stock has returned 0.6% over the last week and 220.9% over the past year, even though the year to date return sits at a 5.1% decline and the five year return is a 25.4% decline. Recent headlines have focused on Warner Bros. Discovery's positioning across streaming, film, and TV content, as...

Lemonade (LMND) opened Q1 2026 earnings season with Q4 2025 revenue of US$228.4 million and a basic EPS loss of US$0.29, alongside net income excluding extra items of a US$21.7 million loss. Over the past year, the company reported quarterly revenue increasing from US$151.2 million in Q1 2025 to US$228.4 million in Q4 2025, while quarterly basic EPS losses narrowed from US$0.86 in Q1 2025 to US$0.29 in Q4 2025. For investors, the latest results focus attention on how quickly Lemonade can...

St. Joe (JOE) opened 2026 with Q1 revenue of US$99 million and basic EPS of US$0.24, compared with Q1 2025 revenue of US$94 million and EPS of US$0.30. Trailing twelve month EPS stood at US$1.94 on revenue of US$518 million. Over that same twelve month stretch, net income reached US$112 million, giving investors a fuller view of how quarterly earnings feed into the broader profit picture. With a net margin of 21.6% over the last year, the latest numbers keep the spotlight firmly on how...

If you are wondering whether Meritage Homes at around US$67.34 is a bargain or just fairly priced, this breakdown will help you frame what the current share price might actually be offering you. The stock has recently been choppy, with a 3.7% decline over the last 7 days, an 8.9% gain over the past 30 days, and returns of 1.7% year to date and 3.2% over the last year. Recent coverage has focused on how Meritage Homes fits into the broader US homebuilding sector, with attention on its ability...

Wondering if Owens Corning is priced fairly today or offering value at a discount? This breakdown focuses squarely on what you are getting for the price you pay. The stock last closed at US$123.34, with returns of 14.0% over 30 days, 8.1% year to date, and a 13.2% decline over the past year. This puts recent gains and longer term performance in different lights. Recent coverage has focused on how investors are reassessing building and construction related names in light of changing...

Diebold Nixdorf (DBD) has followed up its return to profitability by closing out 2025 with Q4 revenue of US$1,104.2 million and basic EPS of US$1.39, setting the stage for its freshly reported Q1 2026 results. Over the past year, the company has seen quarterly revenue move from US$988.9 million in Q4 2024 to US$841.1 million in Q1 2025, US$915.2 million in Q2 2025, US$945.2 million in Q3 2025, and US$1,104.2 million in Q4 2025. Over the same period, basic EPS shifted from US$0.15 to a loss of...